PDL BioPharma (PDLI) Reports Q3 EPS of $0.18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
PDL BioPharma Reports Third Quarter 2018 Financial Results
November 6, 2018 4:05 PM ESTINCLINE VILLAGE, Nev., Nov. 6, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three and nine months ended September 30, 2018 including:
Third Quarter Financial Highlights
Total revenues of $67.9 million. GAAP net income attributable to PDL's shareholders of $25.6 million or $0.18 per share. Non-GAAP net income attributable to PDL's shareholders of $12.3 million. A reconciliation of GAAP to non-GAAP financial results can be found in Table 3 at the end of this news release. Cash and cash equivalents of $401.0 million as of September 30,... More